• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:59:48 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HEPA alert in real time by email
    SC 13G/A 1 tm216476d35_sc13ga.htm SC 13G/A

     

    CUSIP No: 426897104

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 2)*

     

    Hepion Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    426897104

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 426897104

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

      (5) SOLE VOTING POWER
         
        0
         
      (6) SHARED VOTING POWER **
         
        420,000
         
         
      (7) SOLE DISPOSITIVE POWER
         
        0
         
      (8) SHARED DISPOSITIVE POWER **
         
        420,000

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    420,000

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
        1.3%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 426897104

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

      (5) SOLE VOTING POWER
         
        0
         
      (6) SHARED VOTING POWER **
         
        420,000
         
         
      (7) SOLE DISPOSITIVE POWER
         
        0
         
      (8) SHARED DISPOSITIVE POWER **
         
        420,000

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    420,000

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
        1.3%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 426897104

     

    Item 1.

     

    (a)Name of Issuer

     

    Hepion Pharmaceuticals, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    399 Thornall Street, First Floor, Edison, NJ 08837

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    426897104

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

    CUSIP No: 426897104

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Prospectus (Registration No. 333-249724), filed on November 25, 2020, indicates there were 32,025,153 Shares outstanding as of the completion of the offering of the Shares and the full exercise of the underwriter’s over-allotment option referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 426897104

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control

    Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 426897104

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of   Name: Brian Sopinsky
    Attorney, a copy of which was   Title: Secretary
    previously filed    
         
    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    

     

     
     

     

    CUSIP No: 426897104

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

     

    * Previously filed

     

     

     

    Get the next $HEPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEPA

    DatePrice TargetRatingAnalyst
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HEPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

      MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shar

      5/12/25 4:30:00 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

      MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has entered into a binding letter of intent ("LOI") with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time. The di

      5/7/25 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Announces Reverse Stock Split

      Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on March 18, 2025, and will continue to trade on The Nasdaq Capital

      3/14/25 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

      SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      11/14/24 4:07:59 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hepion Pharmaceuticals Inc.

      SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      2/14/24 3:38:57 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      2/14/22 6:05:01 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Financials

    Live finance-specific insights

    See more
    • Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

      - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t

      11/13/23 4:05:00 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

      EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the

      11/10/23 8:50:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

      - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl

      5/22/23 7:00:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Hepion Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50

      2/28/22 8:01:07 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wijngaard Peter bought $15,350 worth of shares (5,000 units at $3.07), increasing direct ownership by 111% to 9,501 units (SEC Form 4)

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      11/28/23 6:55:05 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Wijngaard Peter bought $16,841 worth of shares (3,000 units at $5.61), increasing direct ownership by 200% to 4,501 units

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      9/20/23 11:27:22 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Foster Robert T bought $8,960 worth of shares (1,600 units at $5.60), increasing direct ownership by 3% to 50,470 units

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      9/19/23 9:01:30 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.

      10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

      5/19/25 5:30:01 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.

      SCHEDULE 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      5/15/25 5:23:33 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Hepion Pharmaceuticals Inc.

      NT 10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

      5/15/25 4:30:28 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Purcell Michael J.

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      3/7/24 4:15:14 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Purcell Michael J.

      3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      3/6/24 4:30:41 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Jacob Gary S

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      2/21/24 8:01:44 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Leadership Updates

    Live Leadership Updates

    See more
    • Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

      EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p

      3/6/24 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theralase(R) Announces Appointment of New Independent Director

      TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o

      6/6/23 7:00:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

      EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. "We are thrilled to welcome individuals of this caliber to our Board," said Hepion's Chairman, Gary S. Jacob, Ph.D. "Mr. Reddi and Dr. Lbiati have a remarkable wealth of experience across all aspects of drug development, from clinical research to med

      6/28/22 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care